Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Liver Regeneration

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Hepatic Portal System

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026

Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026

Same author

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Frontiers in immunology·2026

Same author

A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma.

Annals of hepatology·2025

Same author

Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis.

JHEP reports : innovation in hepatology·2025

Same author

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Nature reviews. Gastroenterology & hepatology·2025

Search research articles

Video Experimental Relacionado

Updated: May 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

El carcinoma hepatocelular es un carcinoma hepatocelular.

Alejandro Forner¹, Josep M Llovet, Jordi Bruix

¹Barcelona Clinic Liver Cancer group, Liver Unit, Hospital Clínic Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.

Lancet (London, England)

|February 23, 2012

Resumen

La vigilancia del carcinoma hepatocelular a través de la ecografía ayuda a la detección temprana de tratamientos potencialmente curativos como la resección o el trasplante. Los casos avanzados pueden beneficiarse de la quimioembolisation o terapias moleculares dirigidas, mejorando las tasas de supervivencia.

Más Videos Relacionados

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Videos de Experimentos Relacionados

Last Updated: May 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Área de la Ciencia:

Hepatología Hepatología.
Oncología Oncología.
Gastroenterología y Gastroenterología.

Sus antecedentes:

El carcinoma hepatocelular (HCC) es una de las principales causas de muerte por cáncer a nivel mundial.
La cirrosis aumenta significativamente el riesgo de desarrollar HCC.
La detección temprana a través de exámenes de detección regulares es crucial para mejorar los resultados de los pacientes.

Objetivo del estudio:

Revisar las estrategias actuales de vigilancia para el carcinoma hepatocelular.
Para discutir varias modalidades de tratamiento para el CHC basado en la etapa de la enfermedad.
Para resaltar los avances en la gestión de HCC y la investigación en curso.

Principales métodos:

Revisión de las directrices clínicas actuales para la vigilancia de HCC.
Análisis de los resultados del tratamiento para la resección, el trasplante de hígado, la ablación y la quimioembolización.
Evaluación de la evidencia para las terapias moleculares dirigidas en el CCH avanzado.

Principales resultados:

Se recomienda la ecografía cada seis meses para pacientes de alto riesgo (cirrosis).
Los tratamientos curativos (resección, trasplante, ablación) son más efectivos para los tumores en etapa temprana.
La quimioembolización y el sorafenib (terapia dirigida molecularmente) muestran beneficios de supervivencia en el CCH avanzado o quimiorresistente.

Conclusiones:

La detección temprana del carcinoma hepatocelular a través de la vigilancia mejora la curabilidad y la supervivencia.
La selección del tratamiento depende de las características del tumor, la función hepática y la elegibilidad del paciente.
La investigación en curso en la patogénesis y las terapias dirigidas es prometedora para el futuro manejo de HCC.